Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists

Am J Med. 2005 May;118(5):552-6. doi: 10.1016/j.amjmed.2005.01.028.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Amyloidosis / drug therapy*
  • Amyloidosis / etiology
  • Amyloidosis / mortality
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Psoriatic / complications
  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Psoriatic / mortality
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / mortality
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Male
  • Middle Aged
  • Prospective Studies
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Spain / epidemiology
  • Spondylitis, Ankylosing / complications
  • Spondylitis, Ankylosing / drug therapy
  • Spondylitis, Ankylosing / mortality
  • Survival Rate
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept